Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Bought by Halter Ferguson Financial Inc.

Halter Ferguson Financial Inc. boosted its stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 123.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 681,334 shares of the company's stock after buying an additional 376,795 shares during the quarter. Candel Therapeutics makes up about 2.4% of Halter Ferguson Financial Inc.'s investment portfolio, making the stock its 6th largest position. Halter Ferguson Financial Inc. owned 2.10% of Candel Therapeutics worth $5,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the stock. Commonwealth Equity Services LLC acquired a new stake in Candel Therapeutics in the 4th quarter valued at $357,000. Charles Schwab Investment Management Inc. boosted its stake in Candel Therapeutics by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 52,190 shares of the company's stock worth $453,000 after purchasing an additional 5,413 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Candel Therapeutics in the fourth quarter worth $329,000. Rhumbline Advisers boosted its stake in Candel Therapeutics by 17.0% in the fourth quarter. Rhumbline Advisers now owns 26,272 shares of the company's stock worth $228,000 after purchasing an additional 3,817 shares in the last quarter. Finally, HB Wealth Management LLC boosted its stake in Candel Therapeutics by 54.1% in the fourth quarter. HB Wealth Management LLC now owns 87,300 shares of the company's stock worth $696,000 after purchasing an additional 30,642 shares in the last quarter. Institutional investors and hedge funds own 13.93% of the company's stock.

Remove Ads

Insider Transactions at Candel Therapeutics

In related news, insider Charles Schoch sold 5,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.83, for a total value of $44,150.00. Following the completion of the sale, the insider now owns 38,038 shares in the company, valued at approximately $335,875.54. This represents a 11.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CTO Seshu Tyagarajan sold 31,278 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the transaction, the chief technology officer now directly owns 85,512 shares of the company's stock, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 77,807 shares of company stock worth $633,534 over the last 90 days. 41.60% of the stock is owned by insiders.

Candel Therapeutics Price Performance

Shares of CADL stock traded down $0.19 on Friday, reaching $8.06. 2,512,356 shares of the stock were exchanged, compared to its average volume of 2,675,572. The stock has a market cap of $261.76 million, a PE ratio of -4.66 and a beta of -1.29. Candel Therapeutics, Inc. has a one year low of $1.42 and a one year high of $14.60. The stock has a 50 day moving average price of $8.22 and a 200 day moving average price of $7.01.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.17). On average, research analysts expect that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CADL. Canaccord Genuity Group boosted their price objective on Candel Therapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Bank of America began coverage on Candel Therapeutics in a research note on Friday, February 7th. They issued a "buy" rating and a $15.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $19.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 14th. Finally, Citigroup assumed coverage on Candel Therapeutics in a research note on Thursday, February 20th. They issued a "buy" rating and a $25.00 price objective on the stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.